If you have been reading about SR9009 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-04-17. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Pratt (JP.1), it was entirely due to Collip's expertise that a far less toxic extract from that of Banting and Best's had been produced in just five weeks (p.288). Moreover, he was certain that, without Collip, the Toronto team would never have had an extract that was safe enough to administer to any human being. Also, according to Pratt (pp.286-288), the (pre-Collip) efforts of Banting and Best had been no improvement upon the work of George Ludwig Zuelzer fifteen years earlier: who, despite having been "on the right track" (in relation to recognizing the potential efficacy of a pancreatic extract in the treatment of diabetes mellitus) and, "even with the able assistance of the staff of the Physiological Institute of the University of Berlin as well as that of the trained chemists of the Schering Company over a period of four years [viz., prior to Zuelzer's 1907 publication], had been unable to lessen its toxicity sufficiently to have it employed clinically" (pp.286-288). By 22 February 1922, the Toronto team were reporting that "the effects observed in depancreatized animals have been paralleled in man", that the condition of seven patients had been "favourably influenced" by the daily injection of the extract, and that "the patients themselves report[ed] a subjective subjective sense of well being and increased vigor for a period following the [extract's] administration".
Such an organization requires the issuing of special laws by the governing state, since they are not covered by the normal administrative structure of the respective states. In 2010 only three Kommunalverbände besonderer Art exist.
== Mechanisms of action == Levonorgestrel is a progestogen, i.e. a progesterone receptor agonist. The hormonal IUD's primary mechanism of action is to prevent fertilization. The levonorgestrel intrauterine system has several contraceptive effects, although thickening of the cervical mucus appears to be the primary effect. Other effects include making the inside of the uterus become fatal to sperm and thinning of the endometrial lining, but this is not the usual function. Ovulation is not inhibited in all cases. Numerous studies have demonstrated that IUDs primarily prevent fertilization, not implantation. In one experiment involving tubal flushing, fertilized eggs were found in half of women not using contraception, but no fertilized eggs were found in women using IUDs. IUDs also decrease the risk of ectopic pregnancy, which further implies that IUDs prevent fertilization.
Sources: en.wikipedia.org
=== Perforated === Perforated steel belts enable the drying media, for example hot air, to be transferred 'through' the belt, so that the air is in contact with all parts of the product on the belt. Normally, manufacturers offer perforated belts with five standard perforation patterns which cover most requirements. Other patterns, with a minimum hole diameter of 0.8 mm (0.03 in.) and different spacing, can be provided to suit specific applications.
By 25 September, an army of around 40,000 Iraqi, Syrian, and Houthi militants were concentrated around the Golan Heights, which the Institute for the Study of War argued was to defend against an Israeli invasion of Lebanon. The number of displaced Lebanese people reached an estimated 500,000. On 26 September, an Israeli strike on a three-story building in Younine killed at least 19 Syrians and a Lebanese person, mostly women or children, and injured eight others. On 27 September, Israel struck Hezbollah's central headquarters in Beirut, targeting Hezbollah leader Hassan Nasrallah. Al-Manar reported that four buildings collapsed in the attack. At least five other people died, including Ali Karaki, Hezbollah's commander of the southern front since 1982, and at least 100 were injured. On 28 September, the Lebanese National News Agency reported that IDF strikes struck civil defense centres and a medical clinic in Taybeh and Deir Siriane killing 11 medical staff and injuring 10 others. On 29 September, an Israeli air strike on a home in Dahr-al-Ain killed at least 11 people. The Lebanese National News Agency reported that at least 17 members of a family were killed and several others were trapped under rubble in an Israeli air strike in Zboud. An Israeli strike in Ain El Delb killed 45 people and injured at least 75 others. An Israeli strike in Bekaa killed 12 people and injured 20 others. On 30 September, Israel informed the United States that it intended to carry out a ground maneuver in Lebanon aimed at clearing Hezbollah's infrastructure along the border.
==== Synroc ==== The Australian Synroc (synthetic rock) is a more sophisticated way to immobilize such waste, and this process may eventually come into commercial use for civil wastes (it is currently being developed for U.S. military wastes). Synroc was invented by Ted Ringwood, a geochemist at the Australian National University. The Synroc contains pyrochlore and cryptomelane type minerals. The original form of Synroc (Synroc C) was designed for the liquid high-level waste (PUREX raffinate) from a light-water reactor. The main minerals in this Synroc are hollandite (BaAl2Ti6O16), zirconolite (CaZrTi2O7) and perovskite (CaTiO3). The zirconolite and perovskite are hosts for the actinides. The strontium and barium will be fixed in the perovskite. The caesium will be fixed in the hollandite. A Synroc waste treatment facility began construction in 2018 at ANSTO.
Of the poetry written at this time, of note is Fern Hill, started while living in New Quay, continued at Blaencwm in July and August 1945 and first published in October 1945 Thomas's nine months in New Quay, said first biographer, Constantine FitzGibbon, were "a second flowering, a period of fertility that recalls the earliest days…[with a] great outpouring of poems", as well as a good deal of other material. His second biographer, Paul Ferris, agreed: "On the grounds of output, the bungalow deserves a plaque of its own." Thomas's third biographer, George Tremlett, concurred, describing the time in New Quay as "one of the most creative periods of Thomas's life." Walford Davies, who co-edited the 1995 definitive edition of the play, has noted that New Quay "was crucial in supplementing the gallery of characters Thomas had to hand for writing Under Milk Wood."
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.